A holding company specializing in the acquisition & growth of software companies
Specializing in the acquisition of software companies in e-business, mobile business and business to business (b2b) commerce
  • Demo Video
  • Private Messages
  • Edit My Profile
  • View/Edit Portfolio

Email Updates

Search

AGORACOM News Flash

AGORACOM CONFERENCE UPDATE

  • 12 More Companies Added To Schedule For Dec 3 & 4. (See Schedule)
  • Keynote Speakers Include Peter Grandich, Eric Coffin (See Speakers)
  • Workshop Presentations Added To Thursday Schedule
  • Investors from over 45 Countries Have Visited
  • Conference Begins 2 Weeks From Today!

Looking forward to seeing all of you there gang.  Registration is free for investors.  AGORACOM Members register with just one click.  Non-members takes less than 60 seconds.  Register here (see form on right hand side)

 

Close

OpenEC Technologies Inc Management

Martyn Armstrong

President & CEO

Chairman, Director, President and CEO of OpenEC Technologies Inc. and its subsidiary, SoftCare EC Solutions, Inc.
 

Mr. Zhongdong Zhou

Co-CEO, Director

Mr. Zhou graduated from Qingdao University in 1985, with a major in Finance. After 12 years with the Qingdao Audit Bureau Mr.Zhou joined  Da-Peng Securities Inc. followed by senior managment posistions with Tiantong Securities Inc. In addition to CEO of Headware, Mr. Zhou has been an Independent Director of Jinjing Technologies Inc. (600586.SH) and Executive Director of Zhongtian International Ltd. (2379.HK) from 2004 to Present.

Michael Chen

CFO

Chief Financial Officer of OpenEC Technologies and its subsidiary SoftCare EC Solutions Inc.

Last changed at 22-Feb-2008 01:36PM

AGORACOM Quick Tips

Start A New HUB. Control. Quality. Refreshing. ... Start One Now
Click To Watch Today's Show

President's D.D.

New feature: Hub Presidents can add important links here.

Stock Quote

Open OCE:CA Stock Quote

Investment Ideas

Like OpenEC Technologies Inc? Then you might also be interested in AlphaRx

AlphaRx
  • Initiated Product Registration in China
  • Moving Towards Pivotal Phase III Trials
  • Multi Billion Dollar Market Opportunity